Previous Article | Next Article 
Journal of Clinical Microbiology, June 2002, p. 2220-2223, Vol. 40, No. 6
0095-1137/02/$04.00+0 DOI: 10.1128/JCM.40.6.2220-2223.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.
Evaluation of the Subtype Specificity of Monoclonal Antibodies Raised against H1 and H3 Subtypes of Human Influenza A Virus Hemagglutinins
Eva Vare
ková,1* Nancy Cox,2 and Alexander Klimov2
Institute of Virology, Slovak Academy of Sciences, 842 45 Bratislava, Slovak Republic,1
Influenza Branch, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 303332
Received 11 October 2001/
Returned for modification 7 January 2002/
Accepted 30 March 2002

ABSTRACT
Three previously described monoclonal antibodies (MAbs) specific
for influenza A(H1) hemagglutinins (HA) revealed high sensitivity
(98.2 to 99.1%) and specificity (100%) when tested against 245
strains of different subtypes. One of them was included in the
World Health Organization's influenza reagent kit for 2001 to
2002. In contrast, two MAbs raised against human influenza A(H3)
HA revealed cross-reactivity with viruses of other subtypes.

TEXT
The rapid culture assay (RCA) is an effective method for early
detection and for typing and subtyping of epidemic viruses directly
from clinical specimens within 18 h after infection using specific,
well-established monoclonal antibodies (MAbs) (
9,
12,
15). Earlier,
a panel of MAbs raised against H1 and H3 subtypes of human influenza
A virus hemagglutinins (HA) was evaluated in the RCA with a
number of human influenza A viruses as well as with other respiratory
viruses (
9). Three MAbs (12L/5, 13L/6, and 18L/4) reacted exclusively
with human viruses of the A(H1N1) subtype. Three other MAbs
(IVA1B10, IVG6, and IIF4/D3) reacted with human influenza A
viruses of H3, but not H2 or H1, subtypes. These data demonstrated
that the MAbs could be useful for subtyping circulating human
influenza viruses. However, cases of human infections with influenza
A(H5N1) and A(H9N2) viruses (
2,
4,
5,
8) indicated a need to
verify the specificity of these MAbs with nonhuman influenza
viruses. In addition, a new genetic and antigenic group of human
influenza A(H1N1) viruses, the A/Beijing/262/95 lineage, appeared
in 1995 (
1,
13). Viruses of this group have a single amino acid
deletion in the HA molecule and are antigenically different
from viruses without the deletion (A/Bayern/7/95 lineage). In
this study, the MAbs previously shown to be specific to the
H1 and H3 subtypes of HA (
9) were tested in the RCA with 54
nonhuman influenza A viruses of different subtypes (H1 to H13).
The H1-specific MAbs were also tested against different strains
from the two currently circulating influenza A(H1N1) lineages,
A/Bayern/7/95 and A/Beijing/262/95.
Influenza A viral isolates (a total of 245) of HA subtypes H1 through H13 and influenza B viruses were grown in MDCK cells or in embryonated eggs. Work with pathogenic avian viruses, including A(H5N1) and A(H9N2) human isolates, was conducted under biosafety level 3+ containment. Generation and purification of MAbs 12L/5, 13L/6, 18L/4, IIF4/D3, and IVA1B10 were described earlier (3, 6, 9, 10). In addition, the following MAbs were used as reference antibodies: (i) a mixture of two MAbs specific to influenza A virus nucleoprotein (pool A) (11); (ii) MAb 107L, specific to influenza A nucleoprotein (10); (iii) MAb HA1-71, specific to viruses of the H3 subtype (7, 15); and (iv) a mixture of two MAbs specific to the nucleoprotein and to the HA of influenza B viruses (pool B) (11). The RCA was described previously (9, 15). The following concentrations or dilutions of antibodies were used: 0.35 µg/ml (12L/5 and 13L/6), 0.5 µg/ml (18L/4, IIF4/D3 and IVA1B10), 0.4 µg/ml (107L), 1:400 (HA1-71), 1:1,000 (pool A), and 1:500 (pool B).
Evaluation of MAbs 12L/5, 13L/6, and 18L/4 in the RCA with nonhuman influenza A viruses of different HA subtypes revealed their high specificity. Two MAbs (13L/6 and 18L/4) demonstrated positive reactions with all four tested avian H1 viruses, while MAb 12L/5 reacted with three of them. Nine of 10 swine H1 viruses were positively stained with all three H1-specific MAbs. One swine H1 virus (A/Swine/Wisconsin/1/76) did not react with 12L/5, 13L/6, or 18L/4. These three MAbs did not react with viruses of other subtypes, including several human H5N1 and H9N2 viruses isolated in Hong Kong in 1997 and 1999, respectively (Table 1).
MAbs 12L/5, 13L/6, and 18L/4 had been tested previously for
their specificity and sensitivity with 200 human viruses of
different subtypes (
9). In this study, they were further evaluated
with an additional 97 human influenza A(H1N1) viruses isolated
during 1994 to 2000 in different countries. Viruses from both
cocirculating lineages (A/Bayern/7/95 and A/Beijing/262/95)
were examined, including strains similar to a recent antigenic
variant from the A/Beijing/262/95 lineage, A/New Caledonia/20/99
(H1N1) (
14). Clear perinuclear staining was observed in cells
infected with all of these human H1N1 isolates when MAbs 12L/5,
13L/6, and 18L/4 were used (Table
2). No reactivity was detected
between these MAbs and 71 recent human A(H3N2) virus isolates,
eight historical (1957 to 1968) H2N2 human viruses, and 15 influenza
B strains from 1998 to 1999 (data not shown). Thus, the sensitivity
of MAbs 12L/5, 13L/6, and 18L/4 was 100% for human viruses and
98.2 to 99.1% when nonhuman viruses also were included (with
100% specificity for each of these MAbs).
Two MAbs, IIF4/D3 and IVA1B10, raised against A/Dunedin/4/73
(H3N2) virus (
6) were also tested for cross-reactivity with
54 viral isolates of various subtypes. Positive cytoplasmic
staining with both MAbs was detected in cells infected with
all five nonhuman H3 viruses. Additionally, MAb IIF4/D3 demonstrated
positive reactions with all tested viruses of the H4, H5, and
H8 subtypes as well as with two H2 viruses, one H6 strain, and
one H13 isolate. No reaction was observed between this MAb and
H1, H7, H9, H10, H11, or H12 viruses. MAb IVA1B10 cross-reacted
with all tested H3 and H4 strains, one H11 virus, and two H13
isolates (Table
1).
Thus, 100% specificity of the H1-specific MAbs 12L/5, 13L/6, and 18L/4 was confirmed in this study. These MAbs demonstrated positive reactions with most tested H1 viruses of nonhuman origin (98.2 to 99.1% sensitivity). Importantly, MAbs 12L/5, 13L/6, and 18L/4 demonstrated 100% sensitivity in detection of viruses from both currently circulating genetic lineages of influenza A(H1N1) viruses, A/Bayern/7/95 and A/Beijing/262/95, including A/New Caledonia/20/99-like viruses (14). Therefore, MAbs 12L/5, 13L/6, and 18L//4 are reliable and sensitive reagents for rapid diagnosis of human influenza A viruses of the H1 subtype.
Antibodies IIF4/D3 and IVA1B10, specific to HA2 and HA1 glycopolypeptides of the H3 HA, respectively (6, 9), were identified earlier as good probes for subtyping human H3 viruses (9). In this study we found that they reacted with nonhuman viruses of different subtypes. Their cross-reactivity with several subtypes of nonhuman isolates should be taken into account when human infection with animal (avian) viruses is suspected.
An RCA that permits type- and subtype-specific detection of influenza viruses in clinical specimens was previously described (15). However, MAb HA2-76, which was used for subtyping influenza A(H1N1) viruses, could differentiate only between H3 and non-H3 (e.g., H1) human strains. This MAb was shown to cross-react with several other subtypes of influenza A viruses, including H9 (7). Replacement of MAb HA2-76 with one of the H1-specific MAbs described here will dramatically improve the specificity of the assay (15) for differentiating between H1 and H3 viruses. Recently, we included MAb 18L/4 in the 2001-2002 World Health Organization (WHO) influenza reagent kits produced at the Centers for Disease Control and Prevention, Atlanta, Ga. Before 2001, these kits included only two MAb pools, one specific for type A (pool A) and one specific for type B (pool B) viruses (11). These pools are used by WHO collaborating laboratories for typing influenza viruses in direct immunofluorescent assays or in the RCA. Adding MAb 18L/4, along with the previously described H3-specific MAb HA1-71 (7), to the WHO kits will improve global surveillance for influenza and increase the ability to differentiate new, potentially pandemic influenza virus strains. Pool A and pool B MAbs allow laboratories to type human influenza A and B viruses, while MAbs 18L/4 and HA1-71 allow laboratories to distinguish between human H1 and H3 isolates. Viral isolates positive in reactions with pool A MAbs but negative in reactions with 18L/4 or HA1-71 must be further tested to determine if influenza A viruses of other subtypes are present. Information received from several WHO collaborating laboratories has confirmed that MAb 18L/4 reacted well with recent (2001 to 2002) H1 viruses.

ACKNOWLEDGMENTS
This work was supported, in part, by the Slovak Academy of Sciences
(grants 2/1103/21 and 2/7046/20).
We thank Elena Uli
ná (Institute of Virology, Bratislava, Slovak Republic) for production of ascitic fluids, and we thank Henrietta Hall, Lynn Cooper (Influenza Branch, Centers for Disease Control and Prevention) and Yipu Lin (Department of Virology, National Institute for Medical Research, London, United Kingdom) for their help in selecting influenza viruses used in this study. We also thank Alan Hay (Department of Virology, National Institute for Medical Research, London, United Kingdom) for helpful discussions and Amynah Janmohamed for help in preparing the manuscript.

FOOTNOTES
* Corresponding author. Mailing address: Institute of Virology, Slovak Academy of Sciences, Dúbravská cesta 9, 842 45 Bratislava, Slovak Republic. Phone: 421-2-59302443. Fax: 421-2-54774284. E-mail:
viruevar{at}nic.savba.sk.


REFERENCES
1
- Cox, N. J., and H. L. Regnery. 1996. Global influenza surveillance: tracking a moving target in a rapidly changing world, p. 591-598. In L. E. Brown, A. W. Hampson, and R. G. Webster (ed.), Options for the control of influenza III. Elsevier Science B.V., Amsterdam, The Netherlands
2
- De Jong, J. C., E. C. J. Claas, A. D. M. E. Osterhaus, R. G. Webster, and W. L. Lim. 1997. A pandemic warning? Nature 389:554.[Medline]
3
- Ey, P. L., S. J. Prowse, and C. R. Jenkin. 1978. Isolation of pure IgG1, IgG2a and IgG2b immunoglobulins from mouse serum using Protein A-Sepharose. Biochemistry 15:429-436.
4
- Lin, Y. P., M. Shaw, V. Gregory, K. Cameron, W. Lim, A. Klimov, K. Subbarao, Y. Guan, S. Krauss, K. Shortridge, R. Webster, N. Cox, and A. Hay. 2000. Avian-to-human transmission of H9N2 influenza virus: relationship between H9N2 and H5N1 human isolates. Proc. Natl. Acad. Sci. USA 97:9654-9658.[Abstract/Free Full Text]
5
- Peiris, M., K. Y. Yuen, C. W. Leung, K. H. Chan, P. L. Ip, R. W. Lai, W. K. Orr, and K. F. Shortridge. 1999. Human infection with influenza H9N2. Lancet 354:916-917.[CrossRef][Medline]
6
- Russ, G., K. Poláková, F. Kostolanský, B. Styk, and M. Van
íková. 1987. Monoclonal antibodies to glycopolypeptides HA1 and HA2 of influenza virus hemagglutinin. Acta Virol. 31:374-386.[Medline]
7
- Sanchéz-Fauquier, A., N. Villanueva, and J. A. Melero. 1987. Isolation of cross-reactive, subtype-specific monoclonal antibodies against influenza virus HA1 and HA2 hemagglutinin subunits. Arch. Virol. 97:251-265.[CrossRef][Medline]
8
- Subbarao, K., A. Klimov, J. Katz, H. Regnery, W. Lim, H. Hall, M., Perdue, D. Swayne, C. Bender, J. Huang, M. Hemphill, T. Row, M. Shaw, X. Xu, K. Fukuda, and N. J. Cox. 1998. Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science 279:393-396.[Abstract/Free Full Text]
9
- Tká
ová, M., E. Vare
ková, I. C. Baker, J. M. Love, and T. Ziegler. 1997. Evaluation of monoclonal antibodies for subtyping of currently circulating human type A influenza viruses. J. Clin. Microbiol. 35:1196-1198.[Abstract]
10
- Vare
ková, E., T. Betáková, V. Mucha, L. Soláriková, F. Kostolanský, M. Waris, and G. Russ. 1995. Preparation of monoclonal antibodies for the diagnosis of influenza A infection using different immunization protocols. J. Immunol. Methods 180:108-116.
11
- Walls, H. H., M. W. Harmon, J. J. Slagle, C. Stocksdale, and A. P. Kendal. 1986. Characterization and evaluation of monoclonal antibodies developed for typing influenza A and B viruses. J. Clin. Microbiol. 23:240-245.[Abstract/Free Full Text]
12
- Waris, M., T. Ziegler, M. Kivivirta, and O. Ruuskanen. 1990. Rapid detection of respiratory syncytial virus and influenza A virus in cell cultures by immunoperoxidase staining with monoclonal antibodies. J. Clin. Microbiol. 28:1159-1162.[Abstract/Free Full Text]
13
- Weekly Epidemiological Record. 1998. Recommended composition of influenza virus vaccines for use in the 1998-1999 season. Wkly. Epidemiol. Rec. 73:56-63.[Medline]
14
- Weekly Epidemiological Record. 1999. Recommended composition of influenza virus vaccines for use in the 1999-2000 season. Wkly. Epidemiol. Rec. 74:57-61.[Medline]
15
- Ziegler, T., H. Hall, A. Sanchéz-Fauquier, W. C. Gamble, and N. J. Cox. 1995. Type- and subtype-specific detection of influenza viruses in clinical specimens by rapid culture assay. J. Clin. Microbiol. 33:318-321.[Abstract]
Journal of Clinical Microbiology, June 2002, p. 2220-2223, Vol. 40, No. 6
0095-1137/02/$04.00+0 DOI: 10.1128/JCM.40.6.2220-2223.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Gocnik, M., Fislova, T., Mucha, V., Sladkova, T., Russ, G., Kostolansky, F., Vareckova, E.
(2008). Antibodies induced by the HA2 glycopolypeptide of influenza virus haemagglutinin improve recovery from influenza A virus infection. J. Gen. Virol.
89: 958-967
[Abstract]
[Full Text]
-
Gocnik, M., Fislova, T., Sladkova, T., Mucha, V., Kostolansky, F., Vareckova, E.
(2007). Antibodies specific to the HA2 glycopolypeptide of influenza A virus haemagglutinin with fusion-inhibition activity contribute to the protection of mice against lethal infection. J. Gen. Virol.
88: 951-955
[Abstract]
[Full Text]